{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T01:01:04Z","timestamp":1781139664555,"version":"3.54.1"},"reference-count":20,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vox Sanguinis"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Objectives<\/jats:title>\n                    <jats:p>Canadian Blood Services implemented a re\u2010entry programme in 2014. Donors deferred because of false\u2010reactive or indeterminate screening tests can provide a specimen for re\u2010entry testing 6\u2009months after their initial test, and resume donating if they test negative for all infectious markers. We evaluated the impact of the programme on donor return and retention, and assessed factors associated with reactive results upon re\u2010entry testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>\n                      Using extracted data from our donor database, we followed up donors who tested false\u2010reactive for hepatitis B virus (HBV), human immunodeficiency virus (HIV) and hepatitis C virus (HCV), from the implementation of the programme on 3 February 2014 until 30 June 2025 (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20098094). We characterized the donors reaching each step of the programme by sex, age, donation status and infection marker. We employed logistic regression to identify important predictors of obtaining reactive results upon re\u2010entry testing.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 17.3% of donors eligible for re\u2010entry testing successfully returned and donated. Re\u2010entry testing participation rates were 35.5%, with repeat and older donors more likely to participate. Among re\u2010entry tested donors, 59.2% tested negative. Most donors continued to donate for multiple years upon re\u2010entry. Upon return, 13.1% tested false reactive on a subsequent donation. False\u2010reactives upon re\u2010entry testing were more likely for first\u2010time donors and less likely when a different assay was employed than for the initially false\u2010reactive.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The implementation of a donor re\u2010entry programme has resulted in donor retention and increases in the blood supply. Sending reminder notifications to eligible donors could increase participation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/vox.70233","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T01:41:16Z","timestamp":1773106876000},"page":"779-788","source":"Crossref","is-referenced-by-count":0,"title":["Re\u2010entry of donors deferred for false\u2010reactive screening tests in Canada: 10\u2009years post implementation"],"prefix":"10.1111","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8472-9936","authenticated-orcid":false,"given":"Chinchin","family":"Wang","sequence":"first","affiliation":[{"name":"Epidemiology and Surveillance Canadian Blood Services  Ottawa Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2519-1109","authenticated-orcid":false,"given":"Steven J.","family":"Drews","sequence":"additional","affiliation":[{"name":"Microbiology Canadian Blood Services  Ottawa Ontario Canada"},{"name":"Department of Laboratory Medicine and Pathology, Faculty of Medicine and Dentistry University of Alberta  Edmonton Alberta Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Bigham","sequence":"additional","affiliation":[{"name":"Medical Laboratory and Stem Cell Services Canadian Blood Services  Ottawa Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9904-9952","authenticated-orcid":false,"given":"Mindy","family":"Goldman","sequence":"additional","affiliation":[{"name":"Donation and Policy Studies Canadian Blood Services  Ottawa Ontario Canada"},{"name":"Department of Pathology and Laboratory Medicine University of Ottawa  Ottawa Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5332-2789","authenticated-orcid":false,"given":"Sheila F.","family":"O'Brien","sequence":"additional","affiliation":[{"name":"Epidemiology and Surveillance Canadian Blood Services  Ottawa Ontario Canada"},{"name":"School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa  Ottawa Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.13796"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2004.09.004"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12675"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2008.01760.x"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-5-25"},{"key":"e_1_2_9_7_1","volume-title":"Clinical guide to transfusion","author":"Drews S","year":"2021"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/v14112545"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.21037\/aob-20-95"},{"key":"e_1_2_9_10_1","volume-title":"Giving blood: the development of an altruistic identity","author":"Piliavin JA","year":"1991"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/voxs.12520"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12644"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.70115"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16613"},{"key":"e_1_2_9_15_1","volume-title":"Revised recommendations for testing whole blood, blood components, source plasma and source leukocytes for antibody to hepatitis C virus encoded antigen (anti\u2010HCV)","author":"Food and Drug Administration C for BE and R","year":"1993"},{"key":"e_1_2_9_16_1","volume-title":"Recommendations for donor screening with a licensed test for HIV\u20101 antigen","author":"Food and Drug Administration C for BE and R","year":"1995"},{"key":"e_1_2_9_17_1","volume-title":"Requalification method for reentry of blood donors deferred because of reactive test results for antibody to hepatitis B core antigen (anti\u2010HBc)","author":"Food and Drug Administration C for BE and R","year":"2010"},{"key":"e_1_2_9_18_1","volume-title":"Nucleic acid testing (NAT) for human immunodeficiency virus type 1 (HIV\u20101) and hepatitis C virus (HCV): testing, product disposition, and donor deferral and reentry: guidance for industry","author":"Food and Drug Administration C for BE and R","year":"2017"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15656"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2003.00386.x"},{"key":"e_1_2_9_21_1","volume-title":"Recommendations for the management of donor and units that are initially reactive for hepatitis B surface antigen (HbsAg)","author":"Food and Drug Administration C for BE and R","year":"1987"}],"container-title":["Vox Sanguinis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.70233","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/vox.70233","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.70233","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:23:08Z","timestamp":1781137388000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vox.70233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1111\/vox.70233"],"URL":"https:\/\/doi.org\/10.1111\/vox.70233","archive":["Portico"],"relation":{},"ISSN":["0042-9007","1423-0410"],"issn-type":[{"value":"0042-9007","type":"print"},{"value":"1423-0410","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]}}}